The Cost-Effectiveness of Compounding Pharmacies - Episode 348

In this episode of the Gladden Longevity podcast, Dr. Gladden interviews Shaun Noorian from Empower Pharmacy, discussing the growth and mission of the pharmacy, the cost-effectiveness of compounding medications, quality standards in compounding, regulatory oversight, and the ongoing controversy surrounding peptides and FDA decisions. The conversation highlights the importance of personalized medicine and the challenges faced by compounding pharmacies in providing affordable and effective treatments for patients. In this conversation, Dr. Gladden and Shaun Noorian discuss the evolving landscape of compounding pharmacies and personalized medicine. They explore the regulatory challenges faced by compounding pharmacies, the promise of new medications like retatrutide, and the role of GLP-1s in health management. The discussion highlights the importance of muscle preservation in weight loss therapies and the advocacy needed to ensure patient access to compounded medications. They emphasize the renaissance of compounding in healthcare, which is making treatments more accessible and affordable for patients.

For Audience

Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe

If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now

Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!

Takeaways

·       Empower Pharmacy has been operational for 17 years and focuses on personalized medicine.

·       Compounding pharmacies are becoming more popular due to their cost-effectiveness compared to commercial options.

·       Quality standards in compounding are well-established and continuously updated.

·       Compounding pharmacies are subject to rigorous regulatory oversight and inspections.

·       The FDA is currently reviewing the status of several peptides for compounding.

·       Recent changes in the FDA advisory committee may impact the approval of new compounds.